Emergency use of eculizumab in impending and manifest myasthenic crisis: a retrospective case series - PubMed
6 hours ago
- #eculizumab
- #emergency therapy
- #myasthenic crisis
- Eculizumab was used as emergency therapy in four AChR antibody-positive patients with impending or manifest myasthenic crisis (MC).
- Patients showed significant improvement in Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scores within 48 hours of eculizumab administration.
- Notable clinical improvements included arterial blood gas normalization, nasogastric tube removal, and successful extubation in some patients.
- No treatment-related adverse events were observed, suggesting a favorable short-term safety profile.
- Triggers for exacerbation included COVID-19 infection, puerperium, PD-1 inhibitor exposure, and common infections.
- The study suggests eculizumab may offer rapid clinical improvement in MC, especially in cases with complement activation triggers.
- Larger prospective studies are needed to validate eculizumab's efficacy and define its role in acute myasthenic exacerbations.